Pfizer Rounds Out Zyrtec Line With Chewable Tablet NDA Approval
This article was originally published in The Tan Sheet
Executive Summary
Pfizer hopes to increase pediatric use of its Rx allergy drug Zyrtec (cetirizine) with new 5 mg and 10 mg chewable tablets formulations, to be available starting in late April and moving to full distribution in early summer
You may also be interested in...
Antihistamine Price Erosion Justifies Forced Switch – WellPoint
WellPoint Health Networks is continuing its campaign to urge a forced Rx-to-OTC switch of low-and non-sedating antihistamines cetirizine, fexofenadine and desloratadine
Pfizer’s Zyrtec Remains Strong As Rx Antihistamine Market Weakens
The many loratadine products now available in the OTC market have not been able to undercut sales for Pfizer's Zyrtec (cetirizine), according to the company
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC